Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats
- PMID: 16779555
- DOI: 10.1007/s00213-006-0424-1
Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats
Abstract
Rationale: SSR149415 ((2S, 4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide), the first selective nonpeptide vasopressin V1b receptor antagonist has been shown to induce antidepressant-and anxiolytic-like effects following systemic administration, whereas intraseptal infusion of the drug engender antidepressant-but not anxiolytic-like effects.
Objectives: Based on recent evidence that V1b receptors are located within the amygdaloid complex, a structure which is well known for its modulatory role of emotional processes, the possible involvement of the different amygdaloid nuclei in the anxiolytic- and/or antidepressant-like effects of SSR149415 was examined.
Methods: Male Sprague-Dawley or Wistar rats were infused with SSR149415 into the central (CeA), the basolateral (BlA), or the medial (MeA) nucleus of the amygdala and tested 10 min after microinjection in the elevated plus-maze or the forced-swimming test, two models typically used for assessing the anxiolytic and antidepressant effects of drugs, respectively.
Results: Microinjection of SSR149415 into the BlA (1-10 ng), but not into the CeA or the MeA, increased the percentage of time spent in the open arms of the elevated plus-maze, indicating anxiolytic-like effects. Furthermore, in the forced-swimming test, microinjection of the drug into the CeA (1, 10, and 100 ng), BlA (1-10 ng), or MeA (100 ng) decreased immobility, an effect which is indicative of an antidepressant-like action. Together, these findings indicate that while the antidepressant-like effects of SSR149415 are mediated by different amygdaloid nuclei, its anxiolytic-like effects appear to involve only the basolateral nucleus of the amygdala. Moreover, these results add further evidence to the role of extrahypothalamic vasopressinergic systems in the control of emotional responses.
Similar articles
-
Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.Neuropsychopharmacology. 2005 Jan;30(1):35-42. doi: 10.1038/sj.npp.1300562. Neuropsychopharmacology. 2005. PMID: 15367924
-
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. doi: 10.1073/pnas.092012099. Epub 2002 Apr 16. Proc Natl Acad Sci U S A. 2002. PMID: 11959912 Free PMC article.
-
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30. doi: 10.1124/jpet.300.3.1122. J Pharmacol Exp Ther. 2002. PMID: 11861823
-
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.CNS Drug Rev. 2005 Spring;11(1):53-68. doi: 10.1111/j.1527-3458.2005.tb00035.x. CNS Drug Rev. 2005. PMID: 15867952 Free PMC article. Review.
-
Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.Curr Pharm Des. 2005;11(12):1549-59. doi: 10.2174/1381612053764797. Curr Pharm Des. 2005. PMID: 15892661 Review.
Cited by
-
Vasopressin V1B Receptor Antagonists as Potential Antidepressants.Int J Neuropsychopharmacol. 2021 Jul 14;24(6):450-463. doi: 10.1093/ijnp/pyab013. Int J Neuropsychopharmacol. 2021. PMID: 33733667 Free PMC article. Review.
-
Angiotensinergic Neurotransmissions in the Medial Amygdala Nucleus Modulate Behavioral Changes in the Forced Swimming Test Evoked by Acute Restraint Stress in Rats.Cells. 2021 May 17;10(5):1217. doi: 10.3390/cells10051217. Cells. 2021. PMID: 34067508 Free PMC article.
-
SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):101-6. doi: 10.1007/s00210-008-0336-1. Epub 2008 Jul 31. Naunyn Schmiedebergs Arch Pharmacol. 2009. PMID: 18668225
-
Vasopressin: behavioral roles of an "original" neuropeptide.Prog Neurobiol. 2008 Jan;84(1):1-24. doi: 10.1016/j.pneurobio.2007.10.007. Epub 2007 Nov 4. Prog Neurobiol. 2008. PMID: 18053631 Free PMC article. Review.
-
Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.CNS Drugs. 2009 Sep;23(9):755-72. doi: 10.2165/11310830-000000000-00000. CNS Drugs. 2009. PMID: 19689166 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical